drugset
drugset / Trial / NCT03904225

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

NCT03904225 ↗

Phase 2 Unknown 220 enrolled Zhejiang Cancer Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

oral administration of Tegio capsules for 12 months for NPC patients with high risk of metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant metastasis，safety was also evaluated.

Timeline

Start
2018-12-14
Primary completion
2022-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegafur-Gimeracil-Oteracil Unknown 60 mg Oral

Indications

nasopharyngeal carcinoma